Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

Starting soon · Not applicable

Conditions studied: Pancreatic Adenocarcinoma, Pancreatic Head Cancer

In brief

"Pancreatic cancer, especially pancreatic ductal adenocarcinoma, is one of the most serious and deadly cancers. Its outlook is very poor, with fewer than 10% of patients surviving five years after diagnosis. This is largely because the disease is often discovered at a late stage and because it frequently comes back even after surgery. When the tumor is located in the head of the pancreas, the only treatment that can potentially cure the disease is a major operation called a pancreaticoduodenectomy, also known as the Whipple procedure. This surgery is now safely performed in specialized hospitals, but it remains complex and carries a high risk of complications. Importantly, even after surgery, cancer cells often remain, leading to a high rate of local recurrence. A newer surgical technique, known as the "artery-first" approach, changes the order of the operation. By carefully exposing a major blood vessel near the pancreas at the beginning of the surgery, surgeons can better assess whether the tumor can be completely removed and can improve the precision of the operation. This research protocol aims to compare this artery-first technique with the standard surgical approach. The goal is to determine whether starting the operation by addressing the artery allows for more complete tumor removal and reduces the risk of cancer coming back in patients with pancreatic cancer of the head of the pancreas."

Key facts

Study ID

NCT07547033

Run by

Assistance Publique - Hôpitaux de Paris

People needed

150

Starts

2026-09-01

Expected to finish

2031-09-01

Last updated by the study team

2026-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary resectable or borderline with isolated veinous contact pancreatic adenocarcinoma (according to the NCCN classification and international consensual definition of Isaji 2018): resectability is evaluated on arterial-phase and portal-phase IV contrast-enhanced multislice CT scan of the pancreas (slice thickness: 2.5 mm), and assessed in a multidisciplinary staff meeting including at least one radiologist and one expert surgeon.
• CT-scan of the thorax and abdomen confirming non-metastatic PAC at least 45 days before inclusion
• MRI of the liver without metastasis performed maximum one month before inclusion
• CA 19.9 (carbohydrate antigen) level ≤ 500 U/mL at the time of inclusion (in absence of cholestasis or biliary drainage)
• Age 18 or over
• Grade 0 or 1 Performans Status (ECOG)
• Normal renal and liver function at the time of inclusion (According to Cockroft and Gault's equation Glomerular Function Rate > 50ml/min/m2; Prothrombin Time > 70%)
• Absolute neutrophil count > 1,500/mm3, platelet count > 100,000/mm3, haemoglobin level > 10 g/dl (transfusions are authorized) at time of inclusion
• Adequate contraception on fertile women
• "Women of childbearing potential (defined as under 50 years of age and without a history of hysterectomy or tubal ligation) must not self-report being pregnant on the day of inclusion."
• Patient who provides a signed written informed consent form
• Patient having the rights to French social insurance

You may not qualify if…

• Pancreatic adenocarcinoma defined as "borderline" with arterial contact, locally advanced, non-resectable, or metastatic.
• Surgical or anesthesiologic contra-indications:
• Non-controlled congestive heart failure - non-treated angina - recent myocardial infarction (in the previous year) - non-controlled AHT (SBP >160 mm or DBP > 100 mm, despite optimal drug treatment), long QT
• Major non-controlled infection
• Major comorbidity that may preclude the surgery
• Severe liver failure
• Any medical, psychological, or social situation that (in the investigator's opinion) could limit (i) the patient's compliance with the protocol or (ii) the ability to obtain or interpret data
• Pregnant or breastfeeding women and women of childbearing age not using effective means of contraception
• Curatorship or guardianship or patient placed under judicial protection
• Participation in other interventional research type 1, clinical investigation or clinical trial during the study
• Secondary exclusion criterion (during surgery):
• Evaluation of abdominal cavity, presenting infra-radiologic metastasis
• Positive tumoral invasion at frozen section after picking on the inter-aortic lymph nodes performed before any irrevocable organ section.
• Anasthaesiologic complication (induction allergy or unprevisible heart disease at induction)
• For fertile women: serological pregnancy test positive before surgery

Where it is running

• CHU Amiens — Amiens, France
• CHU Angers — Angers, France
• CHU Besançon — Besançon, France
• Hôpital Haut Lévêque — Bordeaux, France
• Hôpital Estaing — Clermont-Ferrand, France
• Hôpital François Mitterrand — Dijon, France
• CHU Lille - Hôpital Claude Huriez — Lille, France
• Hôpital Claude Huriez — Lille, France
• CHU Dupuytren 1 — Limoges, France
• Centre Léon Bérard — Lyon, France
• Hôpital de la Croix-Rousse — Lyon, France
• Hôpital Saint Eloi — Montpellier, France
• Hôpitaux de Brabois — Nancy, France
• Chu Nantes — Nantes, France
• Hôpital Ambroise Paré — Paris, France
• Hôpital Beaujon — Paris, France
• Hôpital Cochin — Paris, France
• Hôpital de la Pitié Salpêtrière — Paris, France
• Hôpital Charles-Nicolle — Rouen, France
• CHU Strasbourg — Strasbourg, France
• Hôpital Rangueil — Toulouse, France
• Hôpital Paul Brousse — Villejuif, France
• Institut Gustave Roussy — Villejuif, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.